scholarly journals Visual Outcomes and Prognostic Factors of Large Submacular Hemorrhages Secondary to Polypoidal Choroidal Vasculopathy

2021 ◽  
Vol Volume 15 ◽  
pp. 3557-3562
Author(s):  
Yu Matsuo ◽  
Masatoshi Haruta ◽  
Yumi Ishibashi ◽  
Koki Ishibashi ◽  
Kei Furushima ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Polypoidal Choroidal Vasculopathy ◽  
Visual Outcomes ◽  
Choroidal Vasculopathy

Long‐term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy

2018 ◽  
Vol 46 (8) ◽  
pp. 916-925 ◽  
Author(s):  
Hyun Goo Kang ◽  
Hyunseung Kang ◽  
Suk Ho Byeon ◽  
Sung Soo Kim ◽  
Hyoung Jun Koh ◽  
...  
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Visual Outcomes ◽  
Choroidal Vasculopathy

Photodynamic therapy for polypoidal choroidal vasculopathy: Baseline perimetric results and visual outcomes

2009 ◽  
Vol 53 (6) ◽  
pp. 588-592 ◽  
Author(s):  
Mitsuhiro Imasawa ◽  
Toyoaki Tsumura ◽  
Arata Sekine ◽  
Toyohiko Kikuchi ◽  
Hiroyuki Iijima
Keyword(s):  
Photodynamic Therapy ◽  
Polypoidal Choroidal Vasculopathy ◽  
Visual Outcomes ◽  
Choroidal Vasculopathy

scholarly journals Association of imaging factors derived from convolutional neural network with visual outcomes in age-related macular degeneration and polypoidal choroidal vasculopathy

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Hyungwoo Lee ◽  
Minsu Jang ◽  
Hyung Chan Kim ◽  
Hyewon Chung
Keyword(s):  
Neural Network ◽  
Convolutional Neural Network ◽  
Macular Degeneration ◽  
Polypoidal Choroidal Vasculopathy ◽  
Age Related Macular Degeneration ◽  
Final Visit ◽  
Visual Gain ◽  
Visual Outcomes ◽  
Age Related ◽  
Choroidal Vasculopathy

AbstractWe investigated the association of visual outcome in typical neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) with or without pachychoroid with lesion areas on optical coherence tomography (OCT) quantified by convolutional neural network (CNN) analysis. Treatment-naïve 132 nAMD and 45 PCV eyes treated with ranibizumab or aflibercept for at least 12 months were retrospectively reviewed. Significant factors, including intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED) and subretinal hyperreflective material (SHRM) area quantified by CNN at baseline and 12 months, were analyzed by logistic regression analyses for 3-line visual gain or maintenance of 20/30 Snellen vision. Visual gain at the final visit in nAMD was associated with a smaller SHRM at baseline (OR 0.167, P = 0.03), greater decrease in SRF and SHRM from baseline to month 12 (OR 1.564, P = 0.02; OR 12.877, P = 0.01, respectively). Visual gain in nAMD without pachychoroid was associated with a greater decrease in SRF and SHRM (OR 1.574, P = 0.03, OR 1.775, P = 0.04). No association was found in nAMD with pachychoroid and any type of PCV. Greater decrease in SRF and SHRM from baseline to month 12 was associated with favorable visual outcomes in nAMD without pachychoroid but not in nAMD with pachychoroid and PCV.

Pachychoroid‐phenotype effects on 5‐year visual outcomes of anti‐VEGF monotherapy in polypoidal choroidal vasculopathy

2021 ◽  
Author(s):  
Yuichiro Shimizu ◽  
Manabu Miyata ◽  
Sotaro Ooto ◽  
Masahiro Miyake ◽  
Yuki Mori ◽  
...  
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Visual Outcomes ◽  
Anti Vegf ◽  
Choroidal Vasculopathy
Sign in / Sign up

Export Citation Format

Share Document